We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use.
See Neuraxpharm’s sites
FDFs | LESVI
APIs | INKE
Our R&D area is made up of a team of highly-qualified experienced professionals specialised
in the development of active pharmaceutical ingredients (APIs)
laboratories where professionals with a high level of training
and experience develop and refine the processes for final transfer to Inke's manufacturing plant
Expert in customising products (PSDs) to meet each
technical and regulatory
needs during the development and commercialisation of its medicinal products
EARLY MARKET ENTRIES
Early market entries in those regions without product patent constraints through
Patented synthetic processes (non infringing or improvement patents)
New patented polymorphic forms and salts
Independent expert reports validating our strong patent position
INKE DEVELOPS PATENTS
AND IMPLEMENTS ITS OWN
SYNTHETIC ROUTES AND
POLYMORPHIC FORMS FOR
THE MANUFACTURING OF
INKE IS ABLE TO PROVIDE
SOLUTIONS FOR EARLY
OPPORTUNITIES OR FOR
PRODUCTS REQUIRING IN
DEPTH KNOWLEDGE OF
LEADERSHIP IN APIs
Inke is among the top 10 European API pharmaceutical manufacturing companies with
“THE HIGHEST NUMBER OF EUROPEAN PATENT FILINGS”
MORE THAN 85 GRANTED PATENTS IN FORCE
on new synthetic processes, polymorphic forms and salts
Inke is a sponsoring exhibitor with scientific posters of the
RDD (Respiratory Drug Delivery) Symposia,
the world’s leading event in the respiratory field
Download the scientific posters presented at the RDD:
Process for Obtaining Stable Micronized Glycopyrronium Bromide for Inhaled Treatment of Respiratory Diseases.
RDD Europe 2017. Volume 2, 2017: 243-248.
Comparative Stability Studies Between Air Jet Micronized and Wet Milled Glycopyrronium Bromide Towards Humidity.
Respiratory Drug Delivery 2018. Volume 2, 2018: 429-432.
Process for Reducing Amorphous Content on Micronized Indacaterol Maleate for Dry Powder Inhaler Formulations.
Respiratory Drug Delivery 2018. Volume 2, 2018: 433-436.